Spire Healthcare Share Price – Latest Levels, Chart and Analysis
Spire Healthcare Group plc (LSE: SPI) has experienced significant volatility in recent trading sessions, with shares moving within a wide range as investors assess the private hospital operator’s trajectory. The stock, which constitutes a FTSE 250 listing, has retreated sharply from its 52-week highs, prompting scrutiny of underlying operational performance and broader market sentiment toward UK healthcare providers.
Recent closing prices have varied between approximately 142p and 147p depending on the trading day and data provider, reflecting both intraday volatility and discrepancies between broker platforms. This divergence in reported figures underscores the importance of verifying timestamps when evaluating real-time positions, particularly given the stock’s tendency toward sharp moves on elevated volume.
The current market capitalization registers anywhere from £574 million to nearly £900 million across different financial data sources, a substantial variation that highlights differing calculation methodologies or timing lags. With enterprise value sitting around £2.1 billion and revenue exceeding £1.5 billion annually, Spire remains a significant player in Britain’s private healthcare infrastructure alongside public sector initiatives like Right to Choose ADHD pathways that influence patient flows.
What is the Current Spire Healthcare Share Price?
| Latest Close Range 142.80p – 147.20p |
52-Week Range 143.00p – 256.50p |
Market Cap £574M – £897M |
Recent Change -13.54% (1 year) |
- Shares have declined over 43% from the 52-week high of 256.50p recorded in 2025.
- Trading volumes have spiked significantly on volatile days, reaching 8.18 million shares.
- Market capitalization estimates vary by over £300 million between major financial data providers.
- The current P/E ratio ranges from 15.33x to 40.22x depending on earnings calculation methodology.
- Recent sessions show heightened volatility with intraday ranges exceeding 5%.
- Profit before tax dropped by over 50% year-on-year in the most recent full-year results.
- The dividend yield stands at 1.24%, offering modest income relative to sector peers.
| Metric | Value | Source/Note |
|---|---|---|
| Ticker | SPI (LSE) | London Stock Exchange |
| Last Close Range | 142.80p – 147.20p | HL, AJ Bell, ADVFN (late March 2026) |
| 52-Week High | 256.50p | Multiple sources |
| 52-Week Low | 143.00p | Hargreaves Lansdown |
| Market Cap | £574.39M – £897M | Source-dependent calculation |
| P/E Ratio | 15.33x – 40.22x | HL vs AJ Bell methodologies |
| Dividend Yield | 1.24% | AJ Bell |
| Enterprise Value | ~£2.1B | MarketScreener |
| Revenue (FY2025) | £1,579.80M | Company fundamentals |
| Profit Before Tax (FY2025) | £18.60M | Down from £38.30M (2024) |
| Volume (Recent) | 75,849 – 2.19M | Varies by session |
Spire Healthcare Share Price History and Chart
Long-Term Trajectory
Historical data reveals extreme volatility in Spire Healthcare’s valuation over the past decade. The shares achieved a peak of approximately 630p (£9.88 USD equivalent) on 20 August 2015, before collapsing to roughly 60p ($0.69 USD) during the March 2020 pandemic sell-off. This dramatic range illustrates the cyclical nature of private healthcare equities and their sensitivity to systemic risk events.
Following the 2020 lows, the stock mounted a sustained recovery, reaching 256.50p in 2025. However, recent chart data indicates a decisive break of support levels, with prices retreating to the 140-150p territory last observed in early 2025. The decline from October 2025 levels near 234-237p to current prices represents a compression of roughly 40% in under six months.
Recent Compression Patterns
December 2025 marked a significant inflection point, with the stock closing at 167p before a brief January rally to 179p. March 2026 has proven particularly turbulent, with intraday swings between 179.67p and 191.60p recorded on volume exceeding 1.9 million shares, followed by a rapid descent to the 142-147p range.
Share price data for SPI exhibits significant discrepancies between platforms. Hargreaves Lansdown recorded a 24 March 2026 close at 147.20p, while AJ Bell reported figures near 142.20p for overlapping periods. ADVFN listed 146.20p. These variations typically reflect different timing of data feeds, bid-ask spread snapshots, or adjustments for corporate actions. Investors should verify the exact timestamp and whether figures represent mid-market prices or last-trade executions.
Spire Healthcare Share Price Prediction and Buy/Sell Outlook
Analyst Valuation Metrics
Forward-looking estimates suggest significant P/E compression, with ratios expected to decline from 25.4x in 2025 to approximately 15x in 2026. Enterprise value-to-sales ratios are projected to tighten from 1.32x to 1.22x, indicating analysts anticipate improved revenue conversion efficiency despite recent price weakness.
Adjusted earnings per share tell a divergent story from headline profits. While reported profit before tax fell 51% year-on-year, adjusted EPS actually improved from 8.80p to 9.60p, representing 9% growth. This disconnect suggests significant non-recurring costs or accounting adjustments in the 2025 results that may not affect operational cash generation.
Market Sentiment Considerations
No definitive consensus recommendation emerges from available data sources. Technical indicators point to a persistent downtrend, with the stock trading near 52-week lows. However, fundamental investors might view the 15x forward P/E multiple as attractive relative to historical averages, provided the company can stabilize profit margins after the 2025 contraction.
Recent Spire Healthcare Share Price News and Drop
The 2026 Decline
The magnitude of recent selling has been substantial, with shares falling from 256.50p highs to the current 140-150p range—a retracement exceeding 43%. This decline places the stock among the more significant fallers in the FTSE 250 healthcare sector over the trailing twelve-month period.
Volume and Liquidity Analysis
Trading patterns reveal institutional repositioning. While typical recent volume averages 75,849 shares, volatile sessions have seen participation surge to 8.18 million shares—over 100 times normal activity. Such spikes typically accompany either significant corporate announcements or forced liquidations by large holders, though historical data shows no definitive news catalyst for the March 2026 drops.
While the share price has declined significantly from its 2025 peak, available research does not pinpoint specific corporate announcements or news events driving the full extent of the recent drop. Investors should consult the London Stock Exchange RNS feed for potential updates not reflected in historical price data.
Spire Healthcare shares trade via standard UK brokerage accounts, ISAs, and SIPPs. The wide bid-ask spreads observed recently (up to several pence) suggest relatively lower liquidity compared to FTSE 100 constituents. Large orders may benefit from execution during peak market hours to minimize slippage.
Spire Healthcare Share Price Timeline: Key Dates
- : Historical peak at approximately 630p (£9.88 USD equivalent) — CompaniesMarketCap
- : Pandemic-era low of approximately 60p ($0.69 USD) — CompaniesMarketCap
- : Trading range stabilizes around 234-237p — Stockomendation
- : Year-end close at 167p — Stockomendation
- : Trading at 179.40p — Stockomendation
- : Recent high of 191.60p with volume of 1.95 million shares — Stockomendation
- : Current trading range established between 142-147p — HL, AJ Bell
Price Certainty: Verified Data Versus Market Questions
| Established Information | Unclear or Pending Information |
|---|---|
| Current share price range: 142-147p (late March 2026) | Exact timing and catalyst for recovery to previous highs |
| 52-week range definitively spans 143p-256.50p | Specific news events driving the March 2026 volatility |
| Market cap calculations vary between £574M and £897M | Which calculation methodology (diluted vs basic) is most accurate |
| P/E ratios range from 15.33x to 40.22x | Consensus analyst price targets for 2026 |
| Dividend yield confirmed at 1.24% | Future dividend sustainability given profit decline |
| Revenue growth: £1,511M (2024) to £1,580M (2025) | Impact of NHS policy changes on private healthcare demand |
Market Position and Healthcare Context
Spire operates 39 hospitals and 8 clinics across the United Kingdom, providing private healthcare services ranging from routine diagnostics to complex surgery. As a FTSE 250 constituent, the company occupies a significant position in the listed healthcare sector, though it remains smaller than international hospital conglomerates. The Pharmacy First Scheme represents one of several NHS partnership initiatives that may influence patient flows between public and private sectors, potentially affecting demand for elective procedures.
Financial fundamentals reveal a business growing revenue while struggling with profitability conversion. FY2025 revenue reached £1,579.80 million against £1,511.20 million in FY2024, an increase of 4.5%. However, profit before tax contracted sharply to £18.60 million from £38.30 million—a decline that management attributed to specific cost pressures or one-off items rather than structural demand erosion.
Valuation metrics remain contested among data providers. The enterprise value of approximately £2.1 billion implies significant debt or lease obligations beyond the equity market capitalization. With EV/Sales ratios declining from 1.32x to 1.22x, analysts anticipate improved capital efficiency, though the wide range in P/E ratios reflects fundamental uncertainty about normalized earnings power and the sustainability of recent margin compression.
Data Sources and Market Attribution
Hargreaves Lansdown recorded the 24 March 2026 close at 147.20p, with a trading range of 140.80p-146.40p and a bid-offer spread of 143.80p-144.40p.
— Hargreaves Lansdown market data, March 2026
Spire Healthcare shares reached a 52-week high of 256.50p before declining to current levels around 142-147p, representing a significant retracement from 2025 peaks.
— AJ Bell and Hargreaves Lansdown historical data
Revenue for the year ending 31 December 2025 totaled £1,579.80 million, with adjusted earnings per share of 9.60p indicating 9% growth year-on-year despite lower reported profits.
— Company financial fundamentals via Hargreaves Lansdown
Key Takeaways on Spire Healthcare Shares
Spire Healthcare shares currently trade at a significant discount to 2025 highs, with valuations varying materially between data providers. While revenue growth and EPS improvements suggest underlying operational resilience, the sharp contraction in reported profits and wide valuation ranges indicate persistent uncertainty. The 1.24% dividend yield offers limited downside protection amid the current downtrend. Investors should monitor official RNS announcements for clarity on the factors driving recent price weakness, verify data across multiple brokerage platforms due to observed discrepancies, and consider the company’s £2.1 billion enterprise value when assessing overall financial risk.
Frequently Asked Questions
What is the current Spire Healthcare share price today?
Recent closes range between 142.80p and 147.20p depending on the data provider and specific trading day in late March 2026. Intraday spreads show bid prices around 142.20p-143.80p and offer prices at 142.80p-144.40p. Prices are delayed by at least 15 minutes on most retail platforms.
Why has the Spire Healthcare share price dropped recently?
The stock has fallen from a 52-week high of 256.50p to approximately 140-150p, a decline of over 43%. While no specific definitive news events have been identified in available data explaining the full magnitude, the drop coincides with a 51% year-on-year decline in reported profit before tax.
What is Spire Healthcare’s market capitalization?
Estimates vary significantly by source: Hargreaves Lansdown calculates £574.39 million, AJ Bell reports £751.63 million, and MarketScreener lists approximately £897 million. This discrepancy likely reflects different timing, share count methodologies, or debt adjustments.
Does Spire Healthcare pay a dividend?
Yes, the current dividend yield stands at 1.24% according to AJ Bell data. The company has maintained distributions despite profit volatility, though sustainability depends on future cash flow generation and the ongoing operational turnaround.
Where can I find Spire Healthcare share price chat and discussion?
The ADVFN platform hosts active discussion forums for SPI shares where private investors exchange market commentary and analysis. However, investors should treat user-generated content as speculative and verify all claims against official regulatory news service announcements.
Is Spire Healthcare a buy or sell?
Available research does not provide definitive consensus recommendations. Analyst estimates suggest P/E compression from 25.4x to 15x by 2026, while historical chart data shows a persistent downtrend. The decision depends on individual risk tolerance and views on the UK’s private healthcare demand outlook.
What is the 52-week range for Spire Healthcare shares?
The stock has traded between a low of 143.00p (or 142p on some platforms) and a high of 256.50p over the past 52 weeks. The current price sits near the bottom of this range.
How does the Pharmacy First Scheme affect Spire Healthcare?
The Pharmacy First Scheme allows pharmacies to treat minor conditions, potentially altering patient pathways. While this may reduce minor consultations for private hospitals, the broader impact on Spire’s specialized surgical and diagnostic services remains uncertain.
More related posts
Cleveland Browns vs Minnesota Vikings Match Player Stats
Fence Panels Near Me – Sacramento Stores, Types & Costs
Microsoft Support Phone Number: 24/7 Real Person Help
Can Dogs Have Popcorn? Safety Guide from AKC & Purina
Air Force 1 Black – Sizing for Men, Women, Juniors
How to Fix Slow Startup Windows – Fixes for Windows 10/11
Newspaper – Definition, History, Types and Evolution
Royal Holloway University of London Ranking – UK 35th, QS 461st Analysis
